866-997-4948(US-Canada Toll Free)

P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2019

Published By :

Global Markets Direct

Published Date : Mar 2019

Category :

Pharmaceutical

No. of Pages : 62 Pages

P2X Purinoceptor 3 (P2RX3) - Pipeline Review, H1 2019

Summary

P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report P2X Purinoceptor 3 - Pipeline Review, H1 2019, outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

P2X Purinoceptor 3 (P2RX3) - P2X purinoceptor 3 is a protein encoded by the P2RX3 gene. It belongs to the family of purinoceptors. This receptor functions as a ligand-gated ion channel and transduce ATP-evoked nociceptor activation. This receptor is important for peripheral pain responses, and also participates in pathways controlling urinary bladder volume reflexes. The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 4 and 4 respectively. Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Respiratory, Women's Health, Genito Urinary System And Sex Hormones and Ophthalmology which include indications Chronic Cough, Pain, Visceral Pain, Endometriosis, Inflammatory Pain, Alzheimer's Disease, Cough, Insomnia, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Neuropathic Pain (Neuralgia), Obstructive Sleep Apnea, Ocular Hypertension, Open-Angle Glaucoma, Osteoarthritis Pain and Respiratory Tract Infections.

Furthermore, this report also reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 3 (P2RX3)
- The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlists all their major and minor projects
- The report assesses P2X Purinoceptor 3 (P2RX3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
P2X Purinoceptor 3 (P2RX3) - Overview
P2X Purinoceptor 3 (P2RX3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development
Asana BioSciences LLC
Bayer AG
Beijing Tide Pharmaceutical Co Ltd
Integral Molecular Inc
Merck & Co Inc
Neurim Pharmaceuticals Ltd
Ossianix Inc
Pfizer Inc
Shionogi & Co Ltd
P2X Purinoceptor 3 (P2RX3) - Drug Profiles
ASN-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1817080 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1902607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize P2X3 for Endometriosis and Chronic Cough - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gefapixant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSX-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OSX-300 Backups - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
piromelatine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize P2X3 for Inflammatory Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize P2X3 Receptor for Chronic Pain and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TDI-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P2X Purinoceptor 3 (P2RX3) - Dormant Products
P2X Purinoceptor 3 (P2RX3) - Discontinued Products
P2X Purinoceptor 3 (P2RX3) - Product Development Milestones
Featured News & Press Releases
Dec 12, 2018: Altasciences Contributes to Positive Top-Line Phase 1 Results for Chronic Cough Drug Candidate
Nov 14, 2018: BELLUS Health updates BLU-5937 top-line phase 1 results timeline to November 2018
Oct 31, 2018: Bellus health announces issuance of new U.S. patent claiming P2X3 selectivity as a means of minimizing taste effects for its lead chronic cough drug candidate BLU-5937
Sep 25, 2018: BELLUS Health announces appointment of clinical advisory board
Jul 19, 2018: BELLUS Health Announces Patent Protection Secured in All Major Pharmaceutical Markets for Lead Drug Candidate BLU-5937
Jul 19, 2018: Evotec Receives Milestone Payment For Start Of Phase II Trial In Its Multi-Target Alliance With Bayer
Jul 09, 2018: BELLUS Health Initiates Phase 1 Clinical Study for its Chronic Cough Drug Candidate, BLU-5937
Jun 27, 2018: BELLUS Health Presents BLU-5937 Preclinical Data and Updated Phase 1 Timeline at 2018 International Cough Symposium
Jun 20, 2018: BELLUS Health to Present at the 2018 International Cough Symposium
Sep 18, 2017: BELLUS Health's BLU-5937 Significantly Reduces Cough Without Taste Disturbance in Two Preclinical Models
May 22, 2017: Merck Announces Presentation of Phase 2 Results for MK-7264, an Investigational, P2X3 Receptor Antagonist, Being Evaluated for the Treatment of Chronic Cough
Apr 27, 2017: BELLUS Health to present at Bloom Burton & Co. Healthcare Investor Conference
Apr 24, 2017: BELLUS Health Announces Grant of New U.S. Patent Covering Lead Compound for Chronic Cough
Mar 07, 2017: Phase II Clinical Trial for Treatment of Mild Alzheimer's Disease
Sep 28, 2016: Neurim Pharmaceuticals Announces First Patients Enrollments in ReCOGNITION - Phase II Clinical Trial of Piromelatine for Mild Alzheimers Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indication, H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019 (Contd..1), H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by Asana BioSciences LLC, H1 2019
Pipeline by Bayer AG, H1 2019
Pipeline by Beijing Tide Pharmaceutical Co Ltd, H1 2019
Pipeline by Integral Molecular Inc, H1 2019
Pipeline by Merck & Co Inc, H1 2019
Pipeline by Neurim Pharmaceuticals Ltd, H1 2019
Pipeline by Ossianix Inc, H1 2019
Pipeline by Pfizer Inc, H1 2019
Pipeline by Shionogi & Co Ltd, H1 2019
Dormant Products, H1 2019
Dormant Products, H1 2019 (Contd..1), H1 2019
Discontinued Products, H1 2019

List of Figures
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *